Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
作者信息
Russell Clark D, Millar Jonathan E, Baillie J Kenneth
机构信息
University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute Edinburgh, Edinburgh, UK.
Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK.
出版信息
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
Abstract
摘要
相似文献
1
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
2
[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. doi: 10.3760/cma.j.issn.1001-0939.2020.03.008.
3
What can we learn about corticosteroid therapy as a treatment for COVID-19?
Osteoporos Int. 2020 Aug;31(8):1595. doi: 10.1007/s00198-020-05487-w. Epub 2020 Jun 9.
4
Dexamethasone in the management of covid -19.
BMJ. 2020 Jul 3;370:m2648. doi: 10.1136/bmj.m2648.
5
On the use of corticosteroids for 2019-nCoV pneumonia.
Lancet. 2020 Feb 29;395(10225):683-684. doi: 10.1016/S0140-6736(20)30361-5. Epub 2020 Feb 12.
6
Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About?
Circ J. 2020 Sep 25;84(10):1887. doi: 10.1253/circj.CJ-20-0462. Epub 2020 Aug 7.
7
[Glucocorticoid for coronavirus disease 2019: a dilemma].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):278. doi: 10.3760/cma.j.cn121430-20200309-00352.
8
Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases.
J Infect Chemother. 2020 Jun;26(6):625-632. doi: 10.1016/j.jiac.2020.04.007. Epub 2020 Apr 16.
9
COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.
Pharmacotherapy. 2020 May;40(5):382-386. doi: 10.1002/phar.2394. Epub 2020 May 4.
10
Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.
AAPS PharmSciTech. 2020 May 13;21(4):130. doi: 10.1208/s12249-020-01679-z.
引用本文的文献
1
Drug utilisation patterns & clinical outcomes in hospitalised COVID-19 patients: A geospatial & machine learning approach.
Indian J Med Res. 2025 Apr;161(4):375-385. doi: 10.25259/IJMR_352_24.
2
Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.
Comput Struct Biotechnol J. 2025 May 22;27:2107-2122. doi: 10.1016/j.csbj.2025.05.033. eCollection 2025.
3
Feature Importance Analysis by Nowcasting Perspective to Predict COVID-19.
Mob Netw Appl. 2022;27(5):1967-1976. doi: 10.1007/s11036-022-01966-y. Epub 2022 Apr 23.
4
[Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology].
Rev Colomb Reumatol. 2020 Jul-Sep;27(3):230-241. doi: 10.1016/j.rcreu.2020.05.007. Epub 2020 Jun 12.
5
Revisiting the role of steroidal therapeutics in the 21st century: an update on FDA approved steroidal drugs (2000-2024).
RSC Med Chem. 2025 May 8. doi: 10.1039/d5md00027k.
6
The comparative effectiveness of methylprednisolone versus dexamethasone on in-hospital mortality in patients with severe or critical COVID-19: a retrospective observational study.
Ther Adv Infect Dis. 2025 Apr 22;12:20499361251328824. doi: 10.1177/20499361251328824. eCollection 2025 Jan-Dec.
7
B cells modulate lung antiviral inflammatory responses via the neurotransmitter acetylcholine.
Nat Immunol. 2025 May;26(5):775-789. doi: 10.1038/s41590-025-02124-8. Epub 2025 Apr 22.
8
Examining efficacy and safety of ethyl acetate extract from as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.
Avicenna J Phytomed. 2024 Nov-Dec;14(6):699-710. doi: 10.22038/AJP.2024.24523.
9
Deep insight into cytokine storm: from pathogenesis to treatment.
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
10
Pharmacological validation of a novel exopolysaccharide from sp. 139 to effectively inhibit cytokine storms.
Heliyon. 2024 Jul 9;10(14):e34392. doi: 10.1016/j.heliyon.2024.e34392. eCollection 2024 Jul 30.
本文引用的文献
1
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
Pharmacological agents for adults with acute respiratory distress syndrome.
Cochrane Database Syst Rev. 2019 Jul 23;7(7):CD004477. doi: 10.1002/14651858.CD004477.pub3.
4
The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis.
Crit Care. 2019 Mar 27;23(1):99. doi: 10.1186/s13054-019-2395-8.
5
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.
N Engl J Med. 2018 Mar 1;378(9):809-818. doi: 10.1056/NEJMoa1705716.
6
Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.
N Engl J Med. 2018 Mar 1;378(9):797-808. doi: 10.1056/NEJMoa1705835. Epub 2018 Jan 19.
7
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome.
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. doi: 10.1164/rccm.201706-1172OC.
8
Middle East Respiratory Syndrome.
N Engl J Med. 2017 Feb 9;376(6):584-594. doi: 10.1056/NEJMsr1408795.
9
The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness.
Chest. 2011 Nov;140(5):1155-1161. doi: 10.1378/chest.11-0047. Epub 2011 May 12.
10
Hemodynamic impact of a positive end-expiratory pressure setting in acute respiratory distress syndrome: importance of the volume status.
Crit Care Med. 2010 Mar;38(3):802-7. doi: 10.1097/CCM.0b013e3181c587fd.
Zotero 插件